메뉴 건너뛰기
American Journal of Gastroenterology
Volumn 111, Issue 5, 2016, Pages 748-749
Ustekinumab and Anti-TNF combination therapy in patients with inflammatory bowel disease
Author keywords

[No Author keywords available]
Indexed keywords

ADALIMUMAB; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; VEDOLIZUMAB; TUMOR NECROSIS FACTOR;
EID: 84966658450     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.66     Document Type: Letter
Times cited : (34)
References (5)
  • 1
    • 84951001359 scopus 로고    scopus 로고
    • Vedolizumab and infliximab combination therapy in the treatment of Crohn?s disease
    • Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn?s disease. Am J Gastroenterol 2015; 110: 1737-8
    • (2015) Am J Gastroenterol , vol.110 , pp. 1737-1738
    • Hirten, R.1    Longman, R.S.2    Bosworth, B.P.3
  • 2
    • 84939266240 scopus 로고    scopus 로고
    • Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in Inflammatory bowel disease: A 14-year experience
    • Freling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in Inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 2015; 110: 1186-96
    • (2015) Am J Gastroenterol , vol.110 , pp. 1186-1196
    • Freling, E.1    Baumann, C.2    Cuny, J.F.3
  • 3
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (phoenix 1
    • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74
    • (2008) Lancet , vol.371 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3
  • 4
    • 84895424744 scopus 로고    scopus 로고
    • Anti-TNF antibody-induced psoriasiform skin lesions in patients with Inflammatory bowel disease are characterised by interferon-γ -expressing Th 1 cells and IL-17A/IL-22-expressing Th 17 cells and respond to anti-IL-12/IL-23 antibody treatment
    • Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with Inflammatory bowel disease are characterised by interferon-γ -expressing Th 1 cells and IL-17A/IL-22-expressing Th 17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567-77
    • (2014) Gut , vol.63 , pp. 567-577
    • Tillack, C.1    Ehmann, L.M.2    Friedrich, M.3
  • 5
    • 84871701834 scopus 로고    scopus 로고
    • Ustekinumab induction and maintenance therapy in refractory Crohn?s disease
    • Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn?s disease. N Engl J Med 2012; 367: 1519-28
    • (2012) N Engl J Med , vol.367 , pp. 1519-1528
    • Sandborn, W.J.1    Gasink, C.2    Gao, L.L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.